**TABLE G28. CHALLENGES SCORES –SLIT– PEDIATRICS**

| **Study** | **Allergen** | **Arms** | **Time of measure** | **Scale description** | **SCORE** | **Value Pre** | **Value post** | **Comparative values** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Hirsch, 199729 | Dust mite | SLITPlacebo | 1 year | nasal provocation (acoustic rhinometry) | SBU/ml 40% reduction nasal flow | 1240470 | 13801790 | SLIT pre vs post p NSPlacebo pre vs post p<0.01SLIT vs Placebo p<0.05 |
| Hirsch, 199729 | Dust mite | SLITPlacebo | 1 year | Bronchial histamine provocation test, PC20 FEV1 (mg/mL) | Concentration inducing 20% reduction of FEV1 | 0.71.7 | 0.521.5 | SLIT vs Placebo p NS |
| la Rosa, 199923Leonardi 200924 | Parietaria | SLITPlacebo | 2 years | ocular conjunctival provocation test | 0-3 | 23 IR/mL18 IR/mL  | 35 15  | SLIT vs Placebo p =0.02 |
| Lue 200619 | Dust mite | SLITPlacebo | 6 months | FEV1 |  | 75 80 | 9082  | SLIT pre vs post p = 0.001Placebo pre vs post p =0.48SLIT vs Placebo p =0.93 |
| Niu200620 | Dust mite | SLITPlacebo | 24 weeks | FEV1 |  | 85 90  | 95 90 | SLIT pre vs post p=0.048Placebo pre vs post p=0.977SLIT vs Placebo NS |
| Ippoliti, 200338 | Dust mite | SLITPlacebo | 6 months | FEV1 |  | 83.480.7 | 92.681.2 | SLIT pre vs post p < 0.001Placebo pre vs post p NSSLIT vs Placebo NR |
| Lue 200619 | Dust mite | SLITPlacebo | 6 months | Morning PEFR |  | 185 210  | 197 225  | SLIT pre vs post p=0.244Placebo pre vs post p=0.086SLIT vs Placebo p=0.132 |
| Lue 200619 | Dust mite | SLITPlacebo | 6 months | Evening PEFR |  | 190 225  | 215 235 | SLIT pre vs post p=0.008Placebo pre vs post p=0.253SLIT vs Placebo p=0.341 |
| Niu 200620 | Dust mite | SLITPlacebo | 24 weeks | PEF |  | 65 70  | 75 77  | SLIT pre vs post p=0.001Placebo pre vs post p=0.075SLIT vs Placebo NSPre/post SLIT: FVC p=0.042, FEV1 p=0.048 |
| Stelmach201127 | Grass mix | SLIT pre-coseasonal SLIT continuousplacebo | 2 years (2010) | FEV1(% predicted) |  | 98.3(2.8 SEM)101.9(2.4)99.7(2.4) | 100.2(2.9)102.8(2.7)102.3(1.9) | No significant changes within and among all groups throughout study. |
| Stelmach201127 | Grass mix | SLIT pre-coseasonal SLIT continuousplacebo | 2 years | Morning PEF(% predicted) | Compare season 2009 to season 2010 | NR | 99.5 (3.1)98 (3.9)90.1 (4.9) | No significant changes within and among all groups throughout study. |
| Stelmach201127 | Grass mix | SLIT pre-coseasonal SLIT continuousplacebo | 2 years | PD20 (mg) |  | NR | 0.25 (0.02)0.19 (0.03)0.25 (0.02) | No significant changes within and among all groups throughout study. |
| Marogna200828 | Birch and Grass | SLITPharma-cotherapy | 3 years | Methacholine challenge | # of patients with positive Mch test | 82 (56.9%)47 (65.3%) | 23 (17.7%)31 (47.7%) | SLIT pre/post, p<0.001,Controls pre/post, NS p=0.5Post: SLIT vs control, p<0.001,OR=0.24 (0.12-0.47) |
| Pajno 200332 Pajno 200433 | Parietaria | SLITPlacebo | 2 years | Methacholine challenge, PC20 (mg/mL) | Compared PC20 in Spring 1999 and Spring 2001 | 3.37 +/- 2.992.44 +/- 2.25 | 9.10 +/- 7.72.46 +/- 2.26 | SLIT pre vs post, p=0.01,Placebo pre vs post, p NSPre: SLIT vs placebo, NSPost: SLIT vs placebo, p=0.001 |
| Pajno 200332 Pajno 200433 | Parietaria | SLITPlacebo | 2 years | FEV1(% predicted) | Spring 1999 compared to Spring 2001 | 82.0 (5.4)78.9 (5.9) | 88.4 (3.7)75.6 (4.9) | SLIT showed trend toward improvement during pollen seasons, although not significant |
| Bahceciler 200130 | Dust Mite | SLITPlacebo | 6 months | Peak Expiratory Flow (%) |  | 97 (77-117)99 (82-128) | 99 (75-116)76 (62-106) | SLIT vs placebo PEF Significant improvement p=0.04SLIT pre vs post, NSPlacebo pre vs post, p=0.028 |
| Bahceciler200130 | Dust Mite | SLITPlacebo | 6 months | FEV1 (%) |  | 95 (75-113)101 (75-115) | 100 (78-119)93 (61-104) | No significant improvement vs placebo |
| Bahceciler200130 | Dust Mite | SLITPlacebo | 6 months | PC20 (mg/ml) |  | 0.28 (0.03-3.8)0.78 (0.04-1.8) | 0.85 (0.17-2.2)0.98 (0.18-3.9) | No significant improvement vs placebo |
| Tari, 199031 | Dust mite | SLITPlacebo | 18 months | Nasal provocation test (NPT) |  | NR | 5.2x increaseNo increase | SLIT vs Placebo p< 0.01Provocation dose significantly increased compared with initial values in SLIT (5.2 x increase), which was not observed in placebo |
| Tari, 199031 | Dust mite | SLITPlacebo | 12 months | Bronchial provocation challenge | FEV-1 Mch challenge (µg)(aspecific) | SLIT group280.8 +/- 16.4 | SLIT group502 +/- 26.6 | SLIT pre vs post, p< 0.05Threshold value increased 1.78x |
| Tari, 199031 | Dust mite | SLITPlacebo | 12 months | Bronchial provocation challenge | FEV1 Dust mite challenge (specific) | SLIT170.8 +/-18.4 | SLIT300.3 +/- 28.4 | SLIT pre vs post p< 0.05Threshold value increased 1.76x |
| Valovirta, 200636Savolainen 200637 | Tree mix | SLIT high doseSLITlow dosePlacebo | Peak season | Conjunctival provocation test | Positive test if 2/4 sx present (itch, red, tears, swelling) | NR | NR | No statistically significant differences between treatment groups |
| Valovirta, 200636Savolainen 200637 | Tree mix | SLIT high doseSLITlow dosePlacebo | Peak season | Methacholine bronchial provocation test (MBPT) | PD20, continued until fall in FEV1 of >20% | NR | NR | No statistically significant differences between treatment groups |